Comprehensive review in current developments of benzimidazole-based medicinal chemistry

Chemical Biology and Drug Design

Volumn 86, Issue 1, 2015, Pages 799-845

  Keri, Rangappa S ^a   Hiremathad, Asha ^a   Budagumpi, Srinivasa ^a   Nagaraja, Bhari Mallanna ^a  

^a JAIN UNIVERSITY   (India)

Author keywords

anticancer; antitubercular; benzimidazole; pharmacological activity; synthesis

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ANALGESIC AGENT; ANTHELMINTIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIPARASITIC AGENT; ANTIPROTOZOAL AGENT; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DIURETIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; TUBERCULOSTATIC AGENT; BENZIMIDAZOLE;

ANALGESIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIULCER ACTIVITY; ARTICLE; CYTOTOXICITY; DIURETIC ACTIVITY; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; MEDICINAL CHEMISTRY; MICROWAVE IRRADIATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMATIC REVIEW; ANIMAL; CHEMISTRY;

ANALGESICS; ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; BENZIMIDAZOLES; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84991200182     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12462     Document Type: Article

References (277)

1. Hobrecker F., (1872) Reduction-products of nitracetamide compounds. Deut Chem Ges Ber; 5: 920-924.
2. Ladenberg A., (1875) Derivatives of diamines. Deut Chem Ges Ber; 8: 677-678.
3. Wundt E., (1878) Derivatives of phenylenediamines. Deut Chem Ges Ber; 11: 826-830.
4. Debus H., (1858) U ber die einwirkung des ammoniaks auf glyoxal. Justus Liebigs Ann Chem; 107: 199-208.
5. Grimmett M.R., (1997) Imidazole and Benzimidazole Synthesis. London: Academic Press.
6. Townsend L.B., Wise D.S., (1990) The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today; 6: 107-112.
7. Valdez J., Cedillo R., Hernandez-Campos A., Yepez L., Hernandez-Luis F., Navarrete-Vazquez G., Tapia A., Cortes R., Hernandezc M., Castilloa R., (2002) Synthesis and antiparasitic activity of 1H-benzimidazole derivatives. Bioorg Med Chem Lett; 12: 2221-2224.
8. Fonseca T., Gigante B., Gilchrist T.L., (2001) A short synthesis of phenanthro[2,3- d]imidazoles from dehydroabietic acid. Application of the methodology as a convenient route to benzimidazoles. Tetrahedron; 57: 1793-1799.
9. Pabba C., Wang H.J., Mulligan S.R., Chen Z.J., Stark T.M., Gregg B.T., (2005) Microwave- assisted synthesis of 1-aryl-1H-indazoles via one-pot two-step Cu-catalyzed intramolecular N-arylation of arylhydrazones. Tetrahedron Lett; 46: 7553-7557.
10. Denny W.A., Rewcastle G.W., Baguley B.C., (1990) Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-Intercalating agents which may not act via topoisomerase II. J Med Chem; 33: 814-819.
11. Gomez H.T., Nunez E.H., Rivera I.L., Alvarez J.G., Rivera R.C., Puc R.M., Ramos R.A., Gutierrez M.C.R., Bacab M.J.C., Vazquez G.N., (2008) Design, synthesis and in vitro antiprotozoal activity of benzimidazolepentamidine hybrids. Bioorg Med Chem Lett; 18: 3147-3151.
12. Porcari A.R., Devivar R.V., Kucera L.S., Drach J.C., Townsend L.B., (1998) Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole. J Med Chem; 41: 1252-1262.
13. Migawa M.T., Girardet J.L., Walker J.A., Koszalka G.W., Chamberlain S.D., Drach J.C., Townsend L.B., (1998) Design, synthesis, and antiviral activity of r-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl) benzimidazoles. J Med Chem; 41: 1242-1251.
14. Tamm I., Sehgal P.B., (1978) Halobenzimidazoleribosides and RNA synthesis of cells and viruses: I. Adv Virus Res; 22: 187-258.
15. Tamm I., (1957) Ribonucleic acid synthesis and influenza virus multiplication. Science; 126: 1235-1236.
16. Roth M., Morningstar M.L., Boyer P.L., Hughes S.H., BuckheitJr R.W., Michejda C.J., (1997) Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-aryl-substituted benzimidazoles. J Med Chem; 40: 4199-4207.
17. Kim J.S., Gatto B., Yu C., Liu A., Liu L.F., La Voie E.J., (1996) Substituted 2,5′-bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem; 39: 992-998.
18. Zarrinmayeh H., Nunes A.M., Ornstein P.L., Zimmerman D.M., Arnold B., Schober D.A., Gackenheimer S.L., Bruns R.F., Hipskind P.A., Britton T.C., Cantrell B.E., Gehlert D.R., (1998) Synthesis and evaluation of a series of novel 2-[(4- chlorophenoxy)methyl]-benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J Med Chem; 41: 2709-2719.
19. Kohara Y., Kubo K., Imamiya E., Wada T., Naka T., Inada Y., (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidicheterocycles as novel tetrazolebioisosteres. J Med Chem; 39: 5228-5235.
20. LaPlante S.R., Jakalian A., Aubry N., Ferland J.M., Bousquet Y., Gillard J., Lefebvre S., Poirier M., Tsantrizos Y.S., Kukolj G., Beaulieu P.L., (2004) Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angew Chem Int Ed Engl; 43: 4306-4311.
21. Wallace M.B., Feng J., Zhang Z., Skene R.J., Shi L., Caster C.L., Kassel D.B., Xu R., Gwaltney S.L., (2008) Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett; 18: 2362-2367.
22. Wright J.B., (1951) The chemistry of the benzimidazoles. Chem Rev; 48: 397-541.
23. Preston P.N., (1974) Synthesis, reactions, and spectroscopic properties of benzimidazoles. Chem Rev; 74: 279-314.
24. McKellar Q.A., Scott E.W., (1990) The benzimidazole anthelmintic agents-A review. J Vet Pharmacol Ther; 13: 223-247.
25. Dubey A.K., Sanyal P.K., (2010) Benzimidazoles in a wormy world. Online Vet J; 5: 63-66.
26. Boiani M., Gonzalez M., (2005) Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev Med Chem; 5: 409-424.
27. Bansal Y., Silakari O., (2012) The therapeutic journey of benzimidazoles. A review. Bioorg Med Chem; 20: 6208-6236.
28. Al-Tel T.H., Al-Qawasmeh R.A., (2010) Post Groebkee-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a] pyrimidine derivatives as potential antimicrobial agents. Eur J Med Chem; 45: 5848-5855.
29. Fang B., Zhou C., Rao X., (2010) Synthesis and biological activities of novel amine-derived bis-azoles as potential antibacterial and antifungal agents. Eur J Med Chem; 45: 4388-4398.
30. Jubie S., Rajeshkumar R., Yellareddy B., Siddhartha G., Sandeep M., Surendrareddy K., Dushyanth H.S., Elango K., (2010) Microwave assisted synthesis of some novel benzimidazole substituted fluoroquinolones and their antimicrobial evaluation. J Pharm Sci Res; 2: 69-76.
31. Dua R., Sonwane S.K., Srivastava S.K., Srivastava S.D., (2010) Conventional and greener approach for the synthesis of some novel substituted -4-oxothiazolidine and their 5-arylidene derivatives of 2-methyl-benzimidazole:antimicrobial activities. J Chem Pharm Res; 2: 415-423.
32. Mungra D.C., Patel M.P., Patel R.G., (2011) Microwave-assisted synthesis of some new tetrazolo [1,5-a]quinoline-based benzimidazoles catalyzed by p-TsOH and investigation of their antimicrobial activity. Med Chem Res; 20: 782-789.
33. Mobinikhaledi A., Foroughifar N., Kalhor M., Mirabolfathy M., (2010) Synthesis and antifungal activity of novel 2-benzimidazolylimino-5-arylidene-4-thiazolidinones. J Heterocyclic Chem; 47: 77-80.
34. Reddy V.A., Reddy K.R., (2010) Synthesis and antimicrobial activity of some novel 4-(1H-benz[d]imidazol-2yl)-1,3-thiazol-2-amines. Chem Pharm Bull; 58: 953-956.
35. Rohini R., Shanker K., Reddy P.M., Ravinder V., (2010) Synthesis and antimicrobial activities of a new class of 6-arylbenzimidazo[1,2-c]quinazolines. J Braz Chem Soc; 21: 2149-2157.
36. Hosamani K.M., Seetharamareddy H.R., Keri R.S., Hanamanthagouda M.S., Moloney M.G., (2009) Microwave assisted, one-pot synthesis of 5-nitro-2-aryl substituted-1H-benzimidazole libraries:screening in vitro for antimicrobial activity. J Enzyme Inhibit Med Chem; 24: 1095-1100.
37. Ranjith P.K., Rajeesh P., Haridas K.R., Susanta N.K., Guru Rowb T.N., Rishikesan R., Kumari N.S., (2013) Design and synthesis of positional isomers of 5 and 6-bromo-1-[(phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazolesas possible antimicrobial and antitubercular agents. Bioorg Med Chem Lett; 23: 5228-5234.
38. Zhou B., Li B., Yi W., Bu X., Mac L., (2013) Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives. Bioorg Med Chem Lett; 23: 3759-3763.
39. Zhang H., Damu G.L.V., Cai G., Zhou C., (2013) Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole. Eur J Med Chem; 64: 329-344.
40. Soni L., Narsinghani T., Sethi A., (2012) Anti-microbial benzimidazole derivatives: synthesis and in vitro biological evaluation. Med Chem Res; 21: 4330-4334.
41. Sathaiah G., Ravi Kumar A., Chandra Shekhar A., Raju K., ShanthanRao P., Narsaiah B., Reddy A.R., Lakshmi D., Sridhar B., (2013) Design and synthesis of positional isomers of 1-alkyl-2-trifluoromethyl-5 or 6-substituted benzimidazoles and their antimicrobial activity. Med Chem Res; 22: 1229-1237.
42. Ravindernath A., Srinivas Reddy M., Sunil V., (2014) Synthesis and biological evaluation of benzo[d]imidazolylchromeno[2,3-d]pyrimidinones. Med Chem Res; 23: 759-764.
43. Desai N.C., Dodiya A.M., Makwana A.H., (2012) Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives. Med Chem Res; 21: 2320-2328.
44. Hosamani K.M., Shingalapur R.V., (2011) Synthesis of 2-mercaptobenzimidazole derivatives as potential anti-microbial and cytotoxic agents. Arch Pharm Chem Life Sci; 11: 311-319.
45. Özkay Y., Tunal Y., Karaca H., Isbox drawings light down and leftkda I., (2010) Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety. Eur J Med Chem; 45: 3293-3298.
46. Li Y.J., Liu L.J., Jin K., Xu Y.T., Sun S.Q., (2010) Synthesis and bioactivity of a novel series of 3,6-disubstituted 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles. Chinese Chem Lett; 21: 293-296.
47. Reddy V.M., Reddy K.R., (2010) Synthesis and antibacterial activity of some novel 6-(1H-benz[d]imidazol-2-yl)-8-(5-nitro-2-furyl)-3-(4-pyridyl)-7,8-dihydro[1,2,4]triazolo[3,4-b] [1,3,4]thiadiazepines. Chem Pharm Bull; 58: 1081-1084.
48. Ansari K.F., Lal C., (2009) Synthesis physicochemical properties and antimicrobial activity of some new benzimidazole derivatives. Eur J Med Chem; 44: 4028-4033.
49. Jadhav G.R., Shaikh M.U., Kale R.P., Ghawalkar A.R., Gill C.H., (2009) Synthesis, characterization, and antimicrobial activities of clubbed [1, 2, 4]-oxadiazoles with fluorobenzimidazoles. J Heterocyclic Chem; 46: 980-987.
50. Sharma D., Narasimhan B., Kumar P., Judge V., Narang R., Clercq E.D., Balzarini J., (2009) Synthesis, antimicrobial and antiviral activity of substituted benzimidazoles. J Enzyme Inhib Med Chem; 24: 1161-1168.
51. Ansari K.F., Lal C., (2009) Synthesis and biological activity of some heterocyclic compounds containing benzimidazole and beta-lactam moiety. J Chem Sci; 121: 1017-1025.
52. Kus C., Sozudonmez F., Altanlar N., (2009) Synthesis and antimicrobial activity of some novel 2-[4-(substituted piperazin-/piperidin-1-ylcarbonyl)phenyl]-1H-benzimidazole derivatives. Arch Pharm Chem Life Sci; 342: 54-60.
53. Ochal1 Z., Bretner M., Wolinowska R., Tyski S., (2013) Synthesis and in vitro antibacterial activity of 5-halogenomethylsulfonyl-benzimidazole and benzotriazole derivatives. Med Chem; 9: 1129-1136.
54. Kumar N.S., Amandoron E.A., Cherkasov A., Finlay B.B., Gong H., Jackson L., Kaur S., et al,. (2012) Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents. Bioorg Med Chem; 20: 7069-7082.
55. Noolvi M., Agrawal S., Patel H., Badiger A., Gaba M., Zambre A., (2014) Synthesis, antimicrobial and cytotoxic activity of novelazetidine-2-one derivatives of 1H-benzimidazole. Arabian J Chem; 7: 219-226.
56. Garudachari B., Satyanarayana M.N., Thippeswamy B., Shivakumar C.K., Shivananda K.N., Hegde G., Isloor A.M., (2012) Synthesis, characterization and antimicrobial studies of some new quinoline incorporated benzimidazole derivatives. Eur J Med Chem; 54: 900-906.
57. Zhang S., Damu G.L.V., Zhang L., Geng R., Zhou C., (2012) Synthesis and biological Evaluation of novel benzimidazole derivatives and their binding behavior with bovine serum albumin. Eur J Med Chem; 55: 164-175.
58. Jardosh H.H., Sangani C.B., Patel M.P., Patel R.G., (2013) One step synthesis of pyrido[1,2-a]benzimidazole derivatives of aryloxypyrazole and their antimicrobial evaluation. Chinese Chem Lett; 24: 123-126.
59. Salahuddin,., Shaharyar M., Mazumder A., Abdullah M.M., (2012) Synthesis, characterization and antimicrobial activity of 1,3,4-oxadiazole bearing 1H-benzimidazole derivatives. Arabian J Chem. In Press, doi: 10.1016/j.arabjc.2012.10.010
60. Karatas H., Alp M., Ybox drawings light down and leftldbox drawings light down and leftz S., Goker H., (2012) Synthesis and potent in vitro activity of novel 1H-benzimidazoles as anti-MRSA agents. Chem Biol Drug Des; 80: 237-244.
61. Medzhitov R., (2010) Inflammation 2010: new adventures of an old flame. Cell; 140: 771-776.
62. Grivennikov S., Greten F.R., Karin M., (2010) Immunity, inflammation, and cancer. Cell; 140: 883-899.
63. Singh P., Mittal A., (2008) Current status of COX-2 inhibitors. Mini Rev Med Chem; 8: 73-90.
64. Achar K.C.S., Hosamani K.M., Seetharamareddy H.R., (2010) In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. Eur J Med Chem; 45: 2048-2054.
65. Gaba M., Singh D., Singh S., Sharma V., Gaba P., (2010) Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulfonyl)-2-methylbenzimidazole derivatives as anti-inflammatory and analgesic agents. Eur J Med Chem; 45: 2245-2249.
66. Sridevi C., Balaji K., Naidu A., Sudhakaran R., (2009) Antioxidant and anti-inflammatory activity of some phenylpyrazolobenzimidazoloquinoxaline derivatives. J Pharma Res; 2: 1500-1503.
67. Jesudason E.P., Sridhar S.K., Padma Malar E.J., Shanmugapandiyan P., Inayathullah M., Arul V., Selvaraj D., Jayakumar R., (2009) Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea. Eur J Med Chem; 44: 2307-2312.
68. Shanmugapandiyan P., Denshing K.S., Ilavarasan R., Anbalagan N., Nirmal R., (2010) Synthesis and biological activity of 2-(thiazolidin-4-one) phenyl]-1H-phenylbenzimidazoles and 2-[4-(azetidin-2-One)-3-chloro-4-phenyl]-1H-phenyl benzimidazoles. Inte J Pharm Sci Drug Res; 2: 115-119.
69. El-Nezhawy A.O.H., Biuomy A.R., Hassan F.S., Ismaiel A.K., Omar H.A., (2013) Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity. Bioorg Med Chem; 21: 1661-1670.
70. Chhajed S.S., Upasani C.D., (2012) Synthesis and in-silico molecular docking simulation of 3-chloro-4-substituted-1-(2-(1H-benzimidazol-2-yl)phenyl))-azetidin-2-ones as novel analgesic anti-inflammatory agent. Arabian J Chem. In Press, doi: 10.1016/j.arabjc.2012.04.038
71. Chen G., Liu Z., Zhang Y., Shan X., Jiang L., Zhao Y., He W., Feng Z., Yang S., Liang G., (2013) Synthesis and anti-inflammatory evaluation of novel benzimidazole and imidazopyridine derivatives. ACS Med Chem Lett; 4: 69-74.
72. Hayashi S., Nakata E., Morita A., Mizuno K., Yamamura K., Kato A., Ohashi K., (2010) Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships. Bioorg Med Chem; 18: 7675-7699.
73. Shaaban M.R., Saleh T.S., Mayhoub A.S., Mansour A., Farag A.M., (2008) Synthesis and analgesic/anti a inflammatory evaluation of fused heterocyclic ring systems incorporating phenylsulfonyl moiety. Bioorg Med Chem; 16: 6344-6352.
74. Kaplancikli Z.A., Turan-Zitouni G., Ozdemir A., Can O.D., Chevallet P., (2009) Synthesis and antinociceptive activities of some pyrazoline derivatives. Eur J Med Chem; 44: 2606-2610.
75. Babu G.S., Rajani N., Malathy P.S., Srinivas B., Kulandaivelu U., Rao J.V., (2010) Synthesis, characterization and evaluation of novel N-(1H-benzimidazol-2-yl)-2-isatinylidene-hydrazinecarboxamide derivatives as anti-inflammatory agents. Der Pharma Chemica; 2: 196-204.
76. Kankala S., Kankala R., Gundepaka P., Thota N., Nerella S., Gangula M., Guguloth H., Kagga M., Vadde R., Vasam C., (2013) Regioselective synthesis of isoxazole- mercaptobenzimidazole hybrids and their in vivo analgesic and anti-inflammatory activity studies. Bioorg Med Chem Lett; 23: 1306-1309.
77. Malesevic M., Gutknecht D., Prell E., Klein C., Schumann M., Nowak R.A., Simon J.C., Schiene-Fischer C., Saalbach A., (2013) Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147. J Med Chem; 56: 7302-7311.
78. Bamborough P., Christopher J.A., Cutler G.J., Dickson M.C., Mellor G.W., Morey J.V., Patel C.B., Shewchuk L.M., (2006) 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-ε kinase. Bioorg Med Chem Lett; 16: 6236-6240.
79. Chen J.J., Thakur K.D., Clark M.P., Laughlin S., George K.M., Bookland R.G., Davis J.R., Cabrera E.J., Easwaran V., De B., Zhang Y.G., (2006) Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3. Bioorg Med Chem Lett; 16: 5633-5638.
80. Nava-Aguilera E., Andersson N., Harris E., Mitchell S., Hamel C., Shea B., Lopez-Vidal Y., Villegas-Arrizon A., Morales-Perez A., (2009) Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis; 13: 17-26.
81. Kishore N., Mishra B.B., Tripathi V., Tiwari V.K., (2009) Alkaloids as potential anti-tubercular agents. Fitoterapia; 80: 149-163.
82. Khasnobis S., Escuyer V.E., Chatterjee D., (2002) Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin Ther Targets; 6: 21-40.
83. Smith P., Moss A., (1994) Tuberculosis: pathogenesis, protection, and control. In:, Bloom B., editor. Epidemiology of Tuberculosis. Washington, DC: ASM Press; p. 47.
84. Shingalapur R.V., Hosamani K.M., Keri R.S., (2009) Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles. Eur J Med Chem; 44: 4244-4248.
85. 37Rv inhibitors as a potential treatment for tuberculosis. Bioorg Med Chem Lett; 18: 6244-6247.
86. Jadhav G.R., Shaikh M.U., Kale R.P., Shiradkar M.R., Gill C.H., (2009) SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazole sas antimicrobial and antituberculosis agents. Eur J Med Chem; 44: 2930-2935.
87. Pandey J., Tiwari V.K., Verma S.S., Chaturvedi V., Bhatnagar S., Sinha S., Gaikwad A.N., Tripathi R.P., (2009) Synthesis and antitubercular screening of imidazole derivatives. Eur J Med Chem; 44: 3350-3355.
88. Kazimierczuk Z., Andrzejewska M., Kaustova J., Klimesova V., (2005) Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazoles. Eur J Med Chem; 40: 203-208.
89. Klimesova V., Koc J., Waisser K., Kaustova J., (2002) New benzimidazole derivatives as antimycobacterial agents. Farmaco; 57: 259-265.
90. Patel R.V., Patel P.K., Kumari P., Rajani D.P., Chikhalia K.H., (2012) Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl)acetamides as antibacterial, antifungal and antituberculosis agents. Eur J Med Chem; 53: 41-51.
91. Kumar K., Awasthi D., Lee S., Zanardi I., Ruzsicska B., Knudson S., Tonge P.J., Slayden R.A., Ojima I., (2011) Novel trisubstitutedbenzimidazoles, targeting MtbFtsZ, as a new class of antitubercular agents. J Med Chem; 54: 374-381.
92. Yoon Y.K., Ali M.A., Wei A.C., Choon T.S., Ismail R., (2013) Synthesis and evaluation of antimycobacterial activity of new benzimidazoleaminoesters. Eur J Med Chem. In Press, doi: 10.1016/j.ejmech.2013.06.025
93. Pieroni M., Tipparaju S.K., Lun S., Song Y., Sturm A.W., Bishai W.R., Kozikowski A.P., (2011) Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. Chem Med Chem; 6: 334-342.
94. Camacho J., Barazarte A., Gamboa N., Rodrigues J., Rojas R., Vaisberg A., Gilman R., Charris J., (2011) Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents. Bioorg Med Chem; 19: 2023-2029.
95. Keane W.F., Brenner B.M., (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the Renaal study. Kidney Int; 63: 1499-1507.
96. Schmidt D., Loscher W., (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia; 46: 858-877.
97. Thiry A., Dogne J.M., Supuran C.T., Masereel B., (2007) Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem; 7: 855-864.
98. Shingalapur R.V., Hosamani K.M., Keri R.S., Hugar M.H., (2010) Derivatives of benzimidazole pharmacophore: synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur J Med Chem; 45: 1753-1759.
99. Vijayakumar K., Ahamed A.J., (2010) Synthesis, anti-tumor, anti-diabetic, and anti- asthmatic activitives of some novel benzimidazole derivatives. J Chem Pharm Res; 2: 215-224.
100. Jain P., Sharma P.K., Rajak H., Pawar R.S., Patil U.K., Singour P., (2010) Design, synthesis and biological evaluation of some novel benzimidazole derivatives for their potential anticonvulsant activity. Arch Pharm Res; 33: 971-980.
101. Vinodkumar R., Vaidya S.D., Kumar B.V.S., Bhise U.N., Bhirud S.B., Mashelkar U.C., (2008) Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(4-phenylethynyl-phenyl)-1H-benzimidazoles and N-substituted 2[4-(4,4-dimethyl-thiochroman-6-yl-ethynyl)-phenyl)-1H benzimidazoles. Eur J Med Chem; 43: 986-995.
102. Kwak H.J., Pyun Y.M., Kim J.Y., Pagire H.S., Kim K.Y., Kim K.R., Rhee S.D., Jung W.H., (2013) Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents. Bioorg Med Chem Lett; 23: 4713-4718.
103. Ushiroda K., Maruta K., Takazawa T., Nagano T., Taiji M., Kohno T., Sato Y., Horai S., Yanagi K., Nagata R., (2011) Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators. Bioorg Med Chem Lett; 21: 1978-1982.
104. Boonstra J., Post J.A., (2004) Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene; 337: 1-13.
105. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B., (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med; 49: 1603-1616.
106. Dumont M., Beal M.F., (2011) Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biol Med; 51: 1014-1026.
107. Ghouleh I.A., Khoo N.K., Knaus U.G., Griendling K.K., Touyz R.M., Thannickal V.J., Barchowsky A., et al,. (2011) Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. J Free Radical Biol Med; 51: 1271-1288.
108. Zhang Y., Tocchetti C.G., Krieg T., Moens A.L., (2012) Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radical Biol Med; 53: 1531-1540.
109. Neochoritis C.G., Zarganes-Tzitzikas T., Tsoleridis C.A., Stephanidou-Stephanatou J., Kontogiorgis C.A., Hadjipavlou-Litina D.J., Choli-Papadopoulou T., (2008) One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol-3(4H)-ones. Eur J Med Chem; 43: 986-995.
110. Ayhan-Kbox drawings light down and leftlcbox drawings light down and leftgil G., Kus C., Ozdamar E.D., Can-Eke B., Iscan M., (2007) Synthesis and antioxidant capacities of some new benzimidazole derivatives. Arch Pharm Chem Life Sci; 340: 607-611.
111. Kerimov I., Ayhan-Kilcigil G., Can-Eke B., Altanlar N., Iscan M., (2007) Synthesis, antifungal and antioxidant screening of some novel benzimidazole derivatives. J Enz Inhib Med Chem; 22: 696-701.
112. Mentes E., Karaali N., Ybox drawings light down and leftlmaz F., Ülker S., Kahveci B., (2013) Microwave-assisted synthesis and biological evaluation of some benzimidazole derivatives containing a 1,2,4-triazol ring. Arch Pharm Chem Life Sci; 346: 556-561.
113. Kerimov I., Ayhan-Kbox drawings light down and leftlcbox drawings light down and leftgil G., Ozdama E.D., Can-Eke B., Coban T., Ozbey S., Kazak C., (2012) Design and one-pot and microwave-assisted synthesis of 2-amino/5-aryl-1,3,4-oxadiazoles bearing a benzimidazole moiety as antioxidants. Arch Pharm Chem Life Sci; 345: 549-556.
114. Upcroft P., Upcroft J.A., (2001) Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev; 14: 150-164.
115. Marshall M.M., Naumovitz D., Ortega Y., Sterling C.R., (1997) Waterborne protozoan pathogens. Clin Microbiol Rev; 10: 67-85.
116. Hernández-Luis F., Hernández-Campos A., Castillo R., Navarrete-Vázquez G., Soria-Arteche O., Hernández-Hernández M., Yépez-Mulia L., (2010) Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and trichinellaspiralis. Eur J Med Chem; 45: 3135-3141.
117. Mavrova A.T., Denkova P., Tsenov Y.A., Anichina K.K., Vutchev D.I., (2007) Synthesis and antitrichinellosis activity of some bis(benzimidazol-2-yl)amines. Bioorg Med Chem; 15: 6291-6297.
118. Pérez-Villanueva J., Hernández-Campos A., Yépez-Mulia L., Méndez-Cuesta C., Méndez-Lucio O., Hernández-Luis F., Castillo R., (2013) Synthesis and antiprotozoal activity of novel 2-{[2-(1H-imidazol-1-yl)ethyl]sulfanyl}-1H-benzimidazole derivatives. Bioorg Med Chem Lett; 23: 4221-4224.
119. Pérez-Villanueva J., Medina-Franco J.L., Caulfield T.R., Hernández-Campos A., Hernández-Luis F., Yépez-Mulia L., Castillo R., (2011) Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of some benzimidazole derivatives with trichomonicidal activity. Eur J Med Chem; 46: 3499-3508.
120. Ismail M.A., Batista-Parra A., Miao Y., Wilson W.D., Wenzler T., Brun R., Boykin D.W., (2005) Dicationic near-linear biphenyl benzimidazole derivatives as DNA-targeted antiprotozoal agents. Bioorg Med Chem; 13: 6718-6726.
121. Ismail M.A., Brun R., Wenzler T., Tanious F.A., Wilson W.D., Boykin D.W., (2004) Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg Med Chem; 12: 5405-5413.
122. Soria-Arteche O., Hernández-Campos A., Yépez-Mulia L., Trejo-Soto P.J., Hernández-Luis F., Gres-Molina J., Maldonado L.A., Castillo R., (2013) Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids. Bioorg Med Chem; 23: 6838-6841.
123. Cai S.X., (2007) Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anti-Cancer Drug Discov; 2: 79-101.
124. Shi L.M., Fan Y., Lee J.K., Waltham M., Andrews D.T., Scherf U., Paull K.D., Weinstein J.N., (2000) Mining and visualizing large anticancer drug discovery databases. J Chem Inf Comput Sci; 40: 367-379.
125. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Wolff V.A., Goodrich M.G., Campbell H., Mayo J., Boyd M.J., (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. Natl Cancer Inst; 83: 757-766.
126. Demirayak S., Kayagil I., Yurttas L., (2011) Microwave supported synthesis of some novel 1,3-Diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem; 46: 411-416.
127. Refaat H.M., (2010) Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives. Eur J Med Chem; 45: 2949-2956.
128. Abdel-Mohsen H.T., Ragab F.A.F., Ramla M.M., El Diwani H.I., (2010) Novel benzimidazole-pyrimidine conjugates as potent antitumor agents. Eur J Med Chem; 45: 2336-2344.
129. Moriarty E., Carr M., Bonham S., Carty M.P., Aldabbagh F., (2010) Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents. Eur J Med Chem; 45: 3762-3769.
130. Fahey K., O'Donovan L., Carr M., Carty M.P., Aldabbagh F., (2010) The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells. Eur J Med Chem; 45: 1873-1879.
131. O'Donovan L., Carty M.P., Aldabbagh F., (2008) First synthesis of N-[(aziridin-2-yl)methyl]benzimidazolequinone and analysis of toxicity towards normal and Fanconi anemia cells. Chem Comm; 43: 5592-5594.
132. Bonham S., O'Donovan L., Carty M.P., Aldabbagh F., (2011) First synthesis of an aziridinyl fused pyrrolo[1,2-a]benzimidazole and toxicity evaluation towards normal and breast cancer cell lines. Org Biomol Chem; 9: 6700-6706.
133. Hranjec M., Starcevic K., Pavelic S.K., Lucin P., Pavelic K., Zamola G.K., (2011) Synthesis, spectroscopic characterization and antiproliferative evaluation in vitro of novel Schiff bases related to benzimidazoles. Eur J Med Chem; 46: 2274-2279.
134. Lewis R.T., Bode C.M., Choquette D.M., Potashman M., Romero K., Stellwagen J.C., Teffera Y., et al,. (2012) The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic Lymphoma Kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem; 55: 6523-6540.
135. Abonia R., Cortés E., Insuasty B., Quiroga J., Nogueras M., Cobo J., (2011) Synthesis of novel 1,2,5-trisubstituted benzimidazoles as potential antitumor agents. Eur J Med Chem; 46: 4062-4070.
136. Luo Y., Xiao F., Qian S., Lu W., Yang B., (2011) Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives. Eur J Med Chem; 46: 417-422.
137. Mavrova A.T., Wesselinova D., Vassilev N., Tsenov J.A., (2011) Synthesis, characterization and cytotoxicity of some novel 1,3-disubstituted-2,3-dihydro-2-iminobenzimidazoles. Eur J Med Chem; 46: 3362-3367.
138. Husain A., Rashid M., Mishra R., Parveen S., Shin D., Kumar D., (2012) Benzimidazole bearing oxadiazole and triazolo-thiadiazoles nucleus: design and synthesis as anticancer agents. Bioorg Med Chem Lett; 22: 5438-5444.
139. Rashid M., Husain A., Mishra R., (2012) Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents. Eur J Med Chem; 54: 855-866.
140. Alkahtani H.M., Abbas A.Y., Wang S., (2012) Synthesis and biological evaluation of benzo[d]imidazole derivative sas potential anti-cancer agents. Bioorg Med Chem Lett; 22: 1317-1321.
141. Determann R., Dreher J., Baumann K., Preu L., Jones P.G., Totzke F., Schächtele C., Kubbutat M.H.G., Kunick C., (2012) 2-Anilino-4-(benzimidazol-2-yl)pyrimidines multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines. Eur J Med Chem; 53: 254-263.
142. El-Nassan H.B., (2012) Synthesis, antitumor activity and SAR study of novel [1, 2, 4]triazino[4,5-a]benzimidazole derivatives. Eur J Med Chem; 53: 22-27.
143. Wang X., Chu N., Wang Q., Liu C., Jiang C., Wang X., Ikejima T., Cheng M., (2012) Newly synthesized bis-benzimidazole derivatives exerting anti-tumor activity through induction of apoptosis and autophagy. Bioorg Med Chem Lett; 22: 6297-6300.
144. Liu T., Sun C., Xing X., Jing L., Tan R., Luo Y., Huang W., Song H., Li Z., Zhao Y., (2012) Synthesis and evaluation of 2-[2-(phenylthiomethyl)-1H-benzo[d]imidazol-1-yl)acetohydrazide derivatives as antitumor agents. Bioorg Med Chem Lett; 22: 3122-3125.
145. Omar M.A., Shaker Y.M., Galal S.A., Ali M.M., Kerwin S.M., Li J., Tokuda H., Ramadan R.A., El Diwani H.I., (2012) Synthesis and docking studies of novel antitumor benzimidazoles. Bioorg Med Chem; 20: 6989-7001.
146. Paul K., Bindal S., Luxami V., (2013) Synthesis of new conjugated coumarin-benzimidazole hybrids and their anticancer activity. Bioorg Med Chem Lett; 2: 3667-3672.
147. Husain A., Rashid M., Shaharyar M., Siddiqui A.A., Mishra R., (2013) Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: new anticancer agents. Eur J Med Chem; 62: 785-798.
148. Wang X., Liu L., Li Y., Sun C., Chen W., Li L., Zhang H., Yang X., (2013) Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents. Eur J Med Chem; 62: 111-121.
149. Mavrov A.T., Wesselinov D., Vassilev N., Tsenov J.A., (2013) Design, synthesis and antiproliferative properties of some new 5-substituted-2-iminobenzimidazole derivatives. Eur J Med Chem; 63: 696-701.
150. Bibian M., Rahaim R.J., Choi J.Y., Noguchi Y., Schürer S., Chen W., Nakanishi S., Licht K., Rosenberg L.H., Li L., Feng Y., Cameron M.D., Duckett D.R., Cleveland J.L., Roush W.R., (2013) Development of highly selective casein kinase 1δ/1ε(CK1δ/ε)inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett; 23: 4374-4380.
151. Liu L., Wang X., Yan J., Li Y., Sun C., Chen W., Zhou B., Zhang H., Yang X., (2013) Synthesis and antitumor activities of novel dibenzo [b,d]furan-imidazole hybrid compounds. Eur J Med Chem; 66: 423-437.
152. Sharma A., Luxami V., Paul K., (2013) Synthesis, single crystal and antitumor activities of benzimidazole-quinazoline hybrids. Bioorg Med Chem Lett; 23: 3288-3294.
153. Puttaraju K.B., Shivashankar K., Chandra M.M., Mahendra M., Rasal V.P., Vivek P.N.V., Rai K., Chanu M.B., (2013) Microwave assisted synthesis of dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones; synthesis, in vitro antimicrobial and anticancer activities of novel coumarin substituted dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones. Eur J Med Chem; 69: 316-322.
154. Chen W., Deng X., Li Y., Yang L., Wana W., Wanga X., Zhang H., Yang X., (2013) Synthesis and cytotoxic activities of novel hybrid 2-phenyl-3-alkylbenzofuran and imidazole/triazole compounds. Bioorg Med Chem Lett; 23: 4297-4302.
155. Refaat H.M., (2012) Synthesis of potential anticancer derivatives of pyrido[1,2-a]benzimidazoles. Med Chem Res; 21: 1253-1260.
156. Masoud G.N., Youssef A.M., Khalek M.M.A., Wahab A.E.A., Labouta I.M., Hazzaa A.A.B., (2013) Design, synthesis, and biological evaluation of new 4-thiazolidinone derivatives substituted with benzimidazole ring as potential chemotherapeutic agents. Med Chem Res; 22: 707-725.
157. Yurttas L., Demirayak S., Ciftci G.A., Ybox drawings light down and leftldbox drawings light down and leftrbox drawings light down and leftm S.U., Kaplancbox drawings light down and leftk Z.A., (2013) Synthesis and biological evaluation of some 1,2- disubstituted benzimidazole derivatives as new potential anticancer agents. Arch Pharm Chem Life Sci; 346: 403-414.
158. Elzahabi H.S.A., (2011) Synthesis, characterization of some benzazoles bearing pyridine moiety: search for novel anticancer agents. Eur J Med Chem; 46: 4025-4034.
159. Renhowe P.A., Pecchi S., Shafer C.M., Machajewski T.D., Jazan E.M., Taylor C., Antonios-McCrea W., et al,. (2009) Design, structure activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem; 52: 278-292.
160. Velaparthi U., Wittman M., Liu P., Carboni J.M., Lee F.Y., Attar R., Balimane P., et al,. (2008) Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem; 51: 5897-5900.
161. Zimmermann K., Wittman M.D., Saulnier M.G., Velaparthi U., Langley D.R., Sang X., Frennesson D., et al,. (2008) Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors. Bioorg Med Chem Lett; 18: 4075-4080.
162. Hranjec M., Pavlovic G., Marjanovic M., Kralj M., Karminski-Zamola G., (2010) Benzimidazole derivatives related to 2,3-acrylonitriles, benzimidazo[1,2-a] quinolines and fluorenes: synthesis, antitumor evaluation in vitro and crystal structure determination. Eur J Med Chem; 45: 2405-2417.
163. Sarhan A.A.O., Al-Dhfyan A., Al-Mozaini M.A., Adra C.N., Aboul-Fadl T., (2010) Cell cycle disruption and apoptotic activity of 3-aminothiazolo[3,2-a]benzimidazole-2-carbonitrile and its homologues. Eur J Med Chem; 45: 2689-2694.
164. Tong Y., Bouska J.J., Ellis P.A., Johnson E.F., Leverson J., Liu X., Marcotte P.A., et al,. (2009) Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J Med Chem; 52: 6803-6813.
165. Chang W., Chang C., Chiang P., Ho Y., Liu J., Chang K., Guh J., (2010) 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. British J Pharm; 160: 1677-1689.
166. Abdel-Aziz H.A., Saleh T.S., El-Zahabi H.S.A., (2010) Facile synthesis and in-vitro antitumor activity of some pyrazolo[3,4-b]pyridines and pyrazolo[1,5-a]pyrimidines linked to a thiazolo[3,2-a]benzimidazole moiety. Arch Pharm Chem Life Sci; 343: 24-30.
167. Wang H., Yu N., Song H., Chen D., Zou Y., Deng W., Lye P.L., et al,. (2009) N-hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity. Bioorg Med Chem Lett; 19: 1403-1408.
168. Wang T., Sepulveda M., Gonzales P., Gately S., (2013) Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents. Bioorg Med Chem Lett; 23: 4790-4793.
169. Rubbiani R., Kitanovic I., Alborzinia H., Can S., Kitanovic A., Onambele L.A., Stefanopoulou M., Geldmacher Y., Sheldrick W.S., Wolber G., Prokop A., Wölfl S., Ott I., (2010) Benzimidazol-2-ylidene gold (I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J Med Chem; 53: 8608-8618.
170. Zheng Y., Zheng M., Ling X., Liu Y., Xue Y., An L., Gu N., Jin M., (2013) Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors. Bioorg Med Chem Lett; 23: 3523-3530.
171. Guo C., Linton A., Jalaie M., Kephart S., Ornelas M., Pairish M., Greasley S., Richardson P., Maegley K., Hickey M., Li J., Wu X., Ji X., Xie Z., (2013) Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg Med Chem Lett; 23: 3358-3363.
172. Nagarajan S., Majumder S., Sharma U., Rajendran S., Kumar N., Chatterjee S., Singh B., (2013) Synthesis and anti-angiogenic activity of benzothiazole, benzimidazole containing phthalimide derivatives. Bioorg Med Chem Lett; 23: 287-290.
173. Bacharaju K., Jambula S.R., Sivan S., Tangeda S.J., Manga V., (2013) Design, synthesis, molecular docking and biological evaluation of new dithiocarbamates substituted benzimidazole and chalcones as possible chemotherapeutic agents. Bioorg Med Chem Lett; 23: 3274-3277.
174. Montaner J.S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A.R., Harrigan P.R., (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet; 368: 531-536.
175. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., et al,. (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med; 359: 1429-1441.
176. Monforte A., Logoteta P., Luca L.D., Iraci N., Ferro S., Maga G., Clercq E.D., Pannecouque C., Chimirri A., (2010) Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem; 18: 1702-1710.
177. Xu Y., Zeng C., Jiao Z., Hu L., Zhong R., (2009) Design, synthesis and anti-HIV integrase evaluation of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives. Molecules; 14: 868-883.
178. 1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem; 16: 7429-7435.
179. Skerlj R., Bridger G., McEachern E., Harwig C., Smith C., Wilson T., Veale D., et al,. (2011) Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. Bioorg Med Chem Lett; 21: 262-266.
180. Sivan S.K., Vangala R., Manga V., (2013) Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors. Bioorg Med Chem; 21: 4591-4599.
181. Tremblay M., Bonneau P., Bousquet Y., DeRoy P., Duan J., Duplessis M., Gagnon A., et al,. (2012) Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold. Bioorg Med Chem Lett; 22: 7512-7517.
182. Ranjan N., Kumar S., Watkins D., Wang D., Appella D.H., Arya D.P., (2013) Recognition of HIV-TAR RNA using neomycin-benzimidazole conjugates. Bioorg Med Chem Lett; 23: 5689-5693.
183. Miller J.F., Turner E.M., Gudmundsson K.S., Jenkinson S., Spaltenstein A., Thomson M., Wheelan P., (2010) Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett; 20: 2125-2128.
184. Ziołkowska N.E., Michejda C.J., Bujacz G.D., (2010) Structure of HIV-1 nonnucleoside reverse transcriptase inhibitors derivatives of N-benzyl-benzimidazole with different substituents in position 4. J Mol Structure; 963: 188-193.
185. Gardiner J.M., Loyns C.R., Burke A., Khan A., Mahmood N., (1995) Synthesis and HIV-1 inhibition of novel benzimidazole derivatives. Bioorg Med Chem Lett; 5: 1251-1254.
186. Miller J.F., Gudmundsson K.S., Richardson L., Jenkinson S., Spaltenstein A., Thomson M., Wheelan P., (2010) Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg Med Chem Lett; 20: 3026-3030.
187. Catalano J.G., Gudmundsson K.S., Svolto A., Boggs S.D., Miller J.F., Spaltenstein A., Thomson M., Wheelan P., Minick D.J., Phelps D.P., Jenkinson S., (2010) Synthesis of a novel tricyclic 1, 2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett; 20: 2186-2190.
188. Gudmundsson K S., Freeman G.A., Drach J.C., Townsend L.B., (2000) Synthesis of fluorosugar analogues of 2,5,6-trichloro-1-(β-d-ribofuranosyl)benzimidazole as antivirals with potentially increased glycosidic bond stability. J Med Chem; 43: 2473-2478.
189. Skerlj R.T., Bridger G.J., Kaller A., McEachern E.J., Crawford J.B., Zhou Y., Atsma B., et al,. (2000) Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem; 53: 3376-3388.
190. Morningstar M.L., Roth T., Farnsworth D.W., Smith M.K., Watson K., Buckheit R.W. Jr, Das K., Zhang W., Arnold E., Julias J.G., Hughes S.H., Michejda C.J., (2007) Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem; 50: 4003-4015.
191. Kazmierski W.M., Anderson D.L., Aquino C., Chauder B.A., Duan M., Ferris R., Kenakin T., et al,. (2011) Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go-related gene (hERG) profile. J Med Chem; 54: 3756-3767.
192. Stupple P.A., Batchelor D.V., Corless M., Dorr P.K., Ellis D., Fenwick D.R., Galan S.R.G., et al,. (2011) An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem; 54: 67-77.
193. Mugnaini C., Rajamaki S., Tintori C., Corelli F., Massa S., Witvrouw M., Debyser Z., Veljkovic V., Botta M., (2007) Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg Med Chem Lett; 17: 5370-5373.
194. Zhu X., Guan J., Xiao Z., Cosentino L M., Lee K., (2004) Anti-AIDS agents. Part 61: anti-HIV activity of new podophyllotoxin derivatives. Bioorg Med Chem; 12: 4267-4273.
195. Lavanchy D., (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect; 17: 107-115.
196. Di Bisceglie A.M., Order S.E., Klein J.L., Waggoner J.G., Sjogren M.H., Kuo G., Houghton M., Choo Q.L., Hoofnagle J.H., (1991) The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol; 86: 335-338.
197. Raimondi S., Bruno S., Mondelli M.U., Maisonneuve P., (2009) Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol; 50: 1142-1154.
198. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales F.L. Jr, Haussinger D., Diago M., Carosi G., Dhumeau D., Craxi A., Chaneac M., Reddy K.R., (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol; 43: 425-433.
199. Beaulieu P.L., (2009) Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Exp Opin Ther Pat; 19: 145-164.
200. Tramontano E., (2008) The exploding field of the HCV polymerase non-nucleoside inhibitors: summary of a first generation compounds. Mini Rev Med Chem; 8: 1298-1310.
201. Lindenbach B.D., Rice C.M., (2005) Unravelling hepatitis C virus replication from genome to function. Nature; 436: 933-938.
202. Soriano V., Peters M.G., Zeuzem S., (2009) New therapies for hepatitis C virus infection. Clin Infect Dis; 48: 313-320.
203. Cao H., Cao R., Zhang H., Zheng X., Gao D., (2008) Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D QSAR and molecular docking studies. Curr Med Chem; 15: 1462-1477.
204. Vitale G., Corona P., Loriga M., Carta A., Paglietti G., Giliberti G., Sanna G., Farci P., Marongiu M.E., La Colla P., (2012) 5-Acetyl-2-arylbenzimidazoles as antiviral agents Part 4. Eur J Med Chem; 53: 83-97.
205. Hwu J.R., Singha R., Hong S.C., Chang Y.H., Das A.R., Vliegen I., De Clercq E., Neyts J., (2008) Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res; 77: 157-168.
206. Luo Y., Yao J., Yang L., Feng C., Tang W., Wang G., Zuo J., Lu W., (2010) Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. Bioorg Med Chem; 18: 5048-5055.
207. Beaulieu P.L., Dansereau N., Duan J., Garneau M., Gillard J., McKercher G., LaPlante S., Lagacée L., Thauvette L., Kukolj G., (2010) Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series. Bioorg Med Chem Lett; 20: 1825-1829.
208. Delang L., Froeyen M., Herdewijn P., Neyts J., (2012) Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. Antiviral Res; 93: 30-38.
209. Ishida T., Suzuki T., Hirashima S., Mizutani K., Yoshida A., Ando I., Ikeda S., Adachi T., Hashimoto H., (2006) Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorg Med Chem Lett; 16: 1859-1863.
210. Tsay S., Hwu J.R., Singha R., Huang W., Chang Y.H., Hsu M., Shieh F., Lin C., Hwang K.C., Horng J., Clercq E.D., Vliegen I., Neyts J., (2013) Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. Eur J Med Chem; 63: 290-298.
211. Tonelli M., Simone M., Tasso B., Novelli F., Boido V., Sparatore F., Paglietti G., Pricl S., Giliberti G., Blois S., Ibba C., Sanna G., Loddo R., Colla P.L., (2010) Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg Med Chem; 18: 2937-2953.
212. Tunitskaya V.L., Mukovnya A.V., Ivanov A.A., Gromyko A.V., Ivanov A.V., Streltsov S.A., Zhuze A.L., Kochetkov S.N., (2011) Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles. Bioorg Med Chem Lett; 21: 5331-5335.
213. Goulet S., Poupart M., Gillard J., Poirier M., Kukolj G., Beaulieu P.L., (2010) Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: implementing parallel synthesis for rapid linker optimization. Bioorg Med Chem Lett; 20: 196-200.
214. Alford C.A., Britt W.J., (1993) Cytomegalovirus. In:, Roizman B., Whitley R.J., Lopez C., editor. The Human Herpesviruses. New York: Raven Press; p. 227-255.
215. Balfour H.H. Jr, (1979) Cytomegalovirus: the troll of transplantation. Arch Intern Med; 139: 279-280.
216. Zhou Y.F., Leon M.B., Waclawiw M.A., Popma J.J., Zu X.Y., Finkel T., Epstein S.E., (1996) Association between prior cytomegalovirus infection and the risk of restenosis after coronary atheroectomy. N Engl J Med; 335: 624-630.
217. Berk T., Gordon S.J., Choi H.Y., Cooper H.S., (1985) Cytomegalovirus infection of the colon: a possible role in the exacerbations of inflammatory bowel disease. J Gastroenterol; 80: 355-360.
218. Crumpacker C.S., (1996) Ganciclovir. N Engl J Med; 335: 721-729.
219. Curran M., Noble S., (2001) Valganciclovir. Drugs; 61: 1145-1150.
220. Townsend L.B., Devivar R.V., Turk S.R., Nassiri M.R., Drach J.C., (1995) Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. J Med Chem; 38: 4098-4105.
221. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A. III, Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W., (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother; 46: 2365-2372.
222. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., Drew W.L., (2002) Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother; 46: 2969-2976.
223. Zou R., Drach J.C., Townsend L.B., (1997) Design, synthesis, andantiviral evaluation of 2-chloro-5,6-dihalo-1-β-D-ribofuranosylbenzimidazolesas potential agents for human cytomegalovirus infections. J Med Chem; 40: 811-818.
224. Patil A., Ganguly S., Surana S., (2010) Synthesis and antiulcer activity of 2-[5-substituted-1H-benzo(d) imidazol-2-yl sulfinyl]methyl-3-substituted quinazoline-4-(3H) ones. J Chem Sci; 122: 443-450.
225. Bariwal J.B., Shah A.K., Kathiravan M.K., Somani R.S., Jagtap J.R., Jain K.S., (2008) Synthesis and antiulcer activity of novel pyrimidylthiomethyl- and pyrimidylsulfinylmethyl benzimidazoles as potential reversible proton pump inhibitors. Indian J Pharm Educ Res; 42: 225-231.
226. Chang C., Liu J., Lin H., Lin C., Tang C., Lue D., Sing Y., Chen L., Kao M., Kuo S., Lai C., (2012) Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells. Eur J Med Chem; 48: 244-254.
227. Khan F.A., Asnani A.J., (2011) Synthesis and antiulcer, anti-secretory activity of some new substituted 2-(pyrimidinylsulfinyl) benzamidazoles derivatives. Int J Res Pharm Biomed Sci; 2: 695-700.
228. Khan F., Nadeem S., (2011) Anti-ulcerogeic effect of 2-(pyrimidinylsulfinyl) benzimidazole derivative against different ulcerogenic agents in rats. Pharmacologyonline; 2: 1217-1222.
229. Patil A., Ganguly S., Hundiwale J., Tayade S., (2012) Synthesis and study of some novel benzimidazole analogs as potential antiulcer agents. Int J Pharm Chem; 2: 89-92.
230. +-ATPase inhibitors. Bull Korean Chem Soc; 22: 1217-1223.
231. +-ATP enzyme inhibitors. Bioorg Med Chem Lett; 21: 4189-4192.
232. Kümmerle A.E., Raimundo J.M., Leal C.M., DaSilva G.S., Balliano T.L., Pereira M.A., de Simone C.A., Sudo R.T., Zapata-Sudo G., Fraga C.A.M., Barreiro E.J., (2009) Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. Eur J Med Chem; 44: 4004-4009.
233. de Champlain J., (2001) Do most antihypertensive agents have a sympatholytic action? Curr Hypertens Rep; 3: 305-313.
234. Bucholz A., Lefker B.A., Ravi-Kiron M.A., (1993) Hypertension therapy: what next? Ann Rep Med Chem; 28: 69-78.
235. Navarrete-Vazquez G., Hidalgo-Figueroa S., Torres-Piedra M., Vergara-Galicia J., Rivera-Leyva J.C., Estrada-Soto S., Leon-Rivera I., Aguilar-Guardarrama B., Rios-Gomez Y., Villalobos-Molina R., Ibarra-Barajas M., (2010) Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives. Bioorg Med Chem; 18: 3985-3991.
236. Jain A., Sharma R., Chaturvedi S.C., (2013) A rational design, synthesis, characterization, and antihypertensive activities of some new substituted benzimidazoles. Med Chem Res; 22: 4622-4632.
237. 2. Der Pharmacia Sinica; 1: 104-115.
238. Sharma M.C., Kohli D.V., Sharma S., (2010) Synthesis and biological evaluation of some new benzimidazoles derivatives 4′-{5-amino-2-[2-substituted-phenylamino)-phenyl-methyl]-benzimidazol-1-ylmethyl}-biphenyl-2-carboxylic acid: nonpeptide angiotensin II receptor antagonists. Int J Drug Deliv; 2: 265-277.
239. Rakeshkumar J., Jawahar J., Pathak D.P., (2006) Synthesis of benzimidazole derivatives: as anti-hypertensive agents. Eur J Chem; 3: 278-285.
240. Alp M., Goker H., Brun R., Ybox drawings light down and leftldbox drawings light down and leftz S., (2009) Synthesis and antiparasitic and antifungal evaluation of 2′-arylsubstituted-1H, 10H-[2,5′]bisbenzimidazolyl-5-carboxamidines. Eur J Med Chem; 44: 2002-2008.
241. Navarrete-Vázquez G., Cedillo R., Hernández-Campos A., Yépez L., Hernández-Luis F., Valdez J., Morales R., Cortés R., Hernández M., Castillo R., (2001) Synthesis and antiparasitic activity of 2-(trifluoromethyl)benzimidazole derivatives. Bioorg Med Chem Lett; 11: 187-190.
242. Radha Y., Manjula K.M., Reddy B.M., Rao B.V., (2011) Synthesis and biological activity of benzimidazoles. Ind J Chem; 50B: 1762-1773.
243. Skerlj R.T., Bastos C.M., Booker M.L., Kramer M.L., Barker R.H., Celatka C.A., O'Shea T.J., Munoz B., Sidhu A.B., Cortese J.F., Wittlin S., Papastogiannidis P., Angulo-Barturen I., Jimenez-Diaz M.B., Edmund S., (2011) Optimization of potent inhibitors of P. falciparum dihydroorotate dehydrogenase for the treatment of malaria. ACS Med Chem Lett; 2: 708-713.
244. Howarth J., Hanlon K., (2001) Novel N-ferrocenylmethyl, N-methyl-2-substituted benzimidazolium iodide salts with in vitro activity against the P. falciparum malarial parasite strain NF54. Tetrahedron Lett; 42: 751-754.
245. Mayence A., Jacques J., Eynde V., Kaiser M., Brun R., Yarlett N., Huang T.L., (2011) Bis(oxyphenylene)benzimidazoles: a novel class of anti-Plasmodium falciparum agents. Bioorg Med Chem; 19: 7493-7500.
246. Ongarora D.S.B., Gut J., Rosenthal P.J., Masimirembwa C.M., Chibale K., (2012) Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: synthesis and pharmacological evaluation. Bioorg Med Chem Lett; 22: 5046-5050.
247. Saify Z.S., Azim M.K., Ahmad W., Nisa M., Goldberg D.E., Hussain S.A., Akhtar S., Akram A., Arayne A., Oksman A., Khan I.A., (2012) New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships. Bioorg Med Chem Lett; 22: 1282-1286.
248. Toro P., Klahn A.H., Pradines B., Lahozd F., Pascual A., Biot C., Arancibia R., (2013) Organometallic benzimidazoles: synthesis, characterization and antimalarial activity. Inorg Chem Comm; 35: 126-129.
249. Nofal Z.M., Srour A.M., El-Eraky W.I., Saleh D.O., Girgis A.S., (2013) Rational design, synthesis and QSAR study of vasorelaxant active 3-pyridinecarbonitriles incorporating 1H-benzimidazol-2-yl function. Eur J Med Chem; 63: 14-21.
250. Di Braccio M., Grossi G., Signorello M.G., Leoncini G., Cichero E., Fossa P., Alfei S., Damonte G., (2013) Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones. Eur J Med Chem; 62: 564-578.
251. Barnard E.A., (1974) Neuromuscular transmission-enzymatic destruction of acetylcholine. In:, Hubbard J.I., editor. The Peripheral Nervous System. New York: Plenum Press; p. 201-224.
252. Jacobsen J.S., (2002) Alzheimer's disease: an overview of current and emerging therapeutic strategies. Curr Top Med Chem; 2: 343-352.
253. Hardy J., Selkoe D.J., (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science; 297: 353-356.
254. Terry R.D., Masliah E., Salmon D.P., (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol; 30: 572-580.
255. Alpan A.S., Parlar S., Carlino L., Tarikogullari A.H., Alptüzün V., Semih Günes H., (2013) Synthesis, biological activity and molecular modeling studies on 1H-benzimidazole derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem; 21: 4928-4937.
256. Zhu J., Wu C., Li X., Wu G., Xie S., Hu Q., Deng Z., Zhu M.X., Luo H., Hong X., (2013) Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem; 21: 4218-4224.
257. Yoon Y.K., Ali M.A., Wei A.C., Choon T.S., Khaw K., Murugaiyah V., Osman H., Masand V.H., (2013) Synthesis, characterization, and molecular docking analysis of novel benzimidazole derivatives as cholinesterase inhibitors. Bioorg Chem; 49: 33-39.
258. Matsumura K., Ono M., Yoshimura M., Kimura H., Watanabe H., Okamoto Y., Ihara M., Takahashi R., Saji H., (2013) Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem; 21: 3356-3362.
259. Matter H., Zoller G., Herling A.W., Sanchez-Arias J., Philippo C., Namane C., Kohlmann M., Pfenninger A., Voss M.D., (2013) Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization. Bioorg Med Chem Lett; 23: 1817-1822.
260. Kim M., Lee J., Jung K., Kim M., Park Y., Ahn H., Kwon Y.H., Hah J., (2013) Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects. Bioorg Med Chem; 21: 2271-2285.
261. Vlahakis J.Z., Vukomanovic D., Nakatsu K., Szarek W.A., (2013) Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): exploration of the effects of substituents at the N-1 position. Bioorg Med Chem; 21: 6788-6795.
262. Baraldi P.G., Baraldi S., Saponaro G., Preti D., Romagnoli R., Piccagli L., Cavalli A., Recanatini M., Moorman A.R., Zaid A.N., Varani K., Borea P.A., Tabrizi M.A., (2012) Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A2B adenosine receptor antagonists. J Med Chem; 55: 797-811.
263. Hamaguchi W., Masuda N., Isomura M., Miyamoto S., Kikuchi S., Amano Y., Honbou K., Mihara T., Watanabe T., (2013) Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition. Bioorg Med Chem; 21: 7612-7623.
264. Sogame S., Suenaga Y., Atobe M., Kawanishi M., Tanaka E., Miyoshi S., (2014) Discovery of a benzimidazole series of ADAMTS-5 (Aggrecanase-2) inhibitors by scaffold hopping. Eur J Med Chem; 71: 250-258.
265. 1 receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles. Eur J Med Chem; 69: 44-54.
266. Taylor S.J., Padyana A.K., Abeywardane A., Liang S., Hao M., De Lombaert S., Proudfoot J., Farmer B.S., Li X., Collins B., Martin L., Albaugh D.R., Hill-Drzewi M., Pullen S.S., Takahashi H., (2013) Discovery of potent, selective chymase inhibitors via fragment linking strategies. J Med Chem; 56: 4465-4481.
267. Hofer S., Kratschmar D.V., Schernthanner B., Vuorinen A., Schuster D., Odermatt A., Easmon J., (2013) Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Bioorg Med Chem; 23: 5397-5400.
268. Qian Y., Conde-Knape K., Erickson S.D., Falcioni F., Gillespie P., Hakimi I., Mennona F., Ren Y., Salari H., So S., Tilley J.W., (2013) Potent MCH-1 receptor antagonists from cis-1,4-diaminocyclohexane-derived indane analogs. Bioorg Med Chem Lett; 23: 4216-4220.
269. Bischoff F., Berthelot D., De Cleyn M., Macdonald G., Minne G., Oehlrich D., Pieters S., et al,. (2012) Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators. J Med Chem; 55: 9089-9106.
270. Bastien D., Ebert M.C.C.J.C., Forge D., Toulouse J., Kadnikova N., Perron F., Mayence A., Huang T.L., Jacques J., Eynde V., Pelletier J.N., (2012) Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase. J Med Chem; 55: 3182-3192.
271. Tamura Y., Omori N., Kouyama N., Nishiura Y., Hayashi K., Watanabe K., Tanaka Y., Chiba T., Yukioka H., Sato H., Okuno T., (2012) Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles. Bioorg Med Chem Lett; 22: 5498-5502.
272. Murray J.M., Sweeney Z.K., Chan B.K., Balazs M., Bradley E., Castanedo G., Chabot C., et al,. (2012) Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. J Med Chem; 55: 7686-7695.
273. Wu Z., Yang C., Xiong Y., Feng Z., Lombardo M., Verras A., Chabin R.M., et al,. (2012) Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine. Bioorg Med Chem Lett; 22: 1774-1778.
274. Banoglu E., Calbox drawings light down and leftskan B., Luderer S., Eren G., Ozkan Y., Altenhofen W., Weinigel C., Barz D., Gerstmeier J., Pergola C., Werz O., (2012) Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). Bioorg Med Chem; 20: 3728-3741.
275. Hua Z., Huang X., Bregman H., Chakka N., DiMauro E.F., Doherty E.M., Goldstein J., et al,. (2012) 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg Med Chem Lett; 22: 5392-5395.
276. Spinks D., Ong H.B., Mpamhanga C.P., Shanks E.J., Robinson D.A., Collie I.T., Read K.D., Frearson J.A., Wyatt P.G., Brenk R., Fairlamb A.H., Gilbert I.H., (2011) Design, synthesis and biological evaluation of novel inhibitors of trypanosoma brucei pteridine reductase 1. Chem Med Chem; 6: 302-308.
277. Cosimelli B., Taliani S., Greco G., Novellino E., Sala A., Severi E., Da Settimo F., et al,. (2011) Derivatives of benzimidazol-2-ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility. Chem Med Chem; 6: 1909-1918.